SCHEDULE 13G: BlackRock Discloses 5% Passive Stake in Tango Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has disclosed a 5.0% passive beneficial ownership stake in Tango Therapeutics, Inc. common stock, totaling 5,457,030 shares.
Summary
- BlackRock, Inc. reported beneficial ownership of 5,457,030 shares of Tango Therapeutics, Inc. common stock.
- This ownership represents 5.0% of the total outstanding common stock of Tango Therapeutics, Inc.
- BlackRock holds sole voting power over 5,323,498 shares and sole dispositive power over 5,457,030 shares.
- The filing is a Schedule 13G, indicating a passive investment, not for the purpose of changing or influencing control of the issuer.
- The filing was made by BlackRock, Inc. as a parent holding company, with various subsidiaries contributing to the aggregate beneficial ownership.
Sentiment
Score: 6
Explanation: The disclosure of a 5.0% passive stake by BlackRock, a major institutional investor, can be viewed as a positive signal of confidence in Tango Therapeutics, Inc. However, the filing itself is a routine regulatory disclosure and does not contain specific operational or financial performance data to significantly alter sentiment.
Positives
- Significant institutional investment from BlackRock, Inc., a major asset manager, may signal confidence in Tango Therapeutics, Inc.
- BlackRock's passive 5.0% stake suggests a long-term, ordinary course of business investment.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by a major institutional asset manager, BlackRock, in a biotechnology company, Tango Therapeutics. Such filings are standard disclosures for institutional investors acquiring more than 5% of a company's stock, signaling a long-term, non-activist position. This type of investment is common across various industries where large funds seek diversified portfolio exposure.
Comparison to Industry Standards
- NA. This Schedule 13G filing is a disclosure of beneficial ownership by an institutional investor and does not contain information comparable to industry-specific operational or financial benchmarks. It does not provide details on comparable companies, projects, or results.
Stakeholder Impact
- The disclosure of BlackRock's 5.0% passive stake may be viewed positively by shareholders as it indicates significant institutional interest and potentially a stable long-term holder. There is no direct impact on employees, customers, suppliers, or creditors mentioned in this filing.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was subsequently revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. signatories. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-17 | Date of filing and signature of the Schedule 13G statement. |
Keywords
BlackRock, Tango Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.